Comparative Pharmacology
Head-to-head clinical analysis: LEVATOL versus NADOLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVATOL versus NADOLOL.
LEVATOL vs NADOLOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Labetalol is a nonselective beta-adrenergic antagonist with additional alpha1-adrenergic blocking activity. It competitively blocks beta1 and beta2 receptors and alpha1 receptors, leading to decreased heart rate, myocardial contractility, and systemic vascular resistance.
Non-selective beta-adrenergic receptor antagonist (beta-blocker) that competitively blocks beta1 and beta2 receptors, reducing heart rate, myocardial contractility, and blood pressure.
50 mg orally once daily, increasing to 100 mg once daily after 2 weeks if tolerated; maximum 200 mg once daily.
40 to 80 mg orally once daily, may be increased at 3-7 day intervals up to 240 mg once daily.
None Documented
None Documented
Clinical Note
moderateNadolol + Digitoxin
"Nadolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateNadolol + Deslanoside
"Nadolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateNadolol + Acetyldigitoxin
"Nadolol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateNadolol + Ouabain
"Nadolol may increase the bradycardic activities of Ouabain."
Terminal elimination half-life is 6-8 hours; prolonged to 10-16 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 14–24 hours (average 20 hours); prolonged in renal impairment (up to 45 hours) allowing once-daily dosing
Renal excretion accounts for 55-60% as unchanged drug; biliary/fecal elimination accounts for 40-45% as metabolites and unchanged drug.
Renal (unchanged drug) 75-85%; fecal/biliary <5%
Category C
Category C
Beta-Blocker
Beta-Blocker